Chicago Capital LLC Lowers Holdings in OmniAb, Inc. (NASDAQ:OABI)

Chicago Capital LLC lowered its stake in shares of OmniAb, Inc. (NASDAQ:OABI - Free Report) by 5.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,975,451 shares of the company's stock after selling 187,104 shares during the period. Chicago Capital LLC owned 2.11% of OmniAb worth $10,533,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of OABI. CWC Advisors LLC. purchased a new stake in shares of OmniAb during the 3rd quarter worth $54,000. Walleye Capital LLC bought a new position in OmniAb in the third quarter worth about $61,000. Intech Investment Management LLC purchased a new stake in shares of OmniAb during the third quarter valued at about $70,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of OmniAb by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company's stock valued at $96,000 after buying an additional 8,909 shares in the last quarter. Finally, Palumbo Wealth Management LLC grew its position in shares of OmniAb by 12.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company's stock worth $104,000 after buying an additional 2,744 shares during the last quarter. Hedge funds and other institutional investors own 72.08% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on OABI shares. Benchmark restated a "buy" rating and issued a $8.00 target price on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reissued a "buy" rating and issued a $11.00 price objective on shares of OmniAb in a research report on Thursday, November 14th.

Insider Buying and Selling at OmniAb

In related news, CEO Matthew W. Foehr sold 41,811 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $135,467.64. Following the sale, the chief executive officer now owns 3,749,639 shares in the company, valued at $12,148,830.36. This represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kurt A. Gustafson sold 15,526 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $50,304.24. Following the transaction, the chief financial officer now directly owns 212,720 shares of the company's stock, valued at $689,212.80. This represents a 6.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,826 shares of company stock worth $268,356. 8.60% of the stock is owned by corporate insiders.

OmniAb Stock Up 4.2 %

Shares of OmniAb stock traded up $0.15 during midday trading on Thursday, hitting $3.71. The company had a trading volume of 705,045 shares, compared to its average volume of 497,739. The company has a fifty day simple moving average of $3.54 and a 200 day simple moving average of $3.98. The stock has a market cap of $523.93 million, a price-to-earnings ratio of -5.98 and a beta of -0.12. OmniAb, Inc. has a 12-month low of $3.10 and a 12-month high of $6.55.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.